Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.

Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, Boehm JS, Ni M, Geisen C, Root DE, Polyak K, Brown M, Richardson AL, Hahn WC, Kaelin WG Jr, Bommi-Reddy A.

Cancer Cell. 2009 Nov 6;16(5):413-24. doi: 10.1016/j.ccr.2009.09.029.

2.

Edging toward new therapeutics with cyclin D1 Egl'ng on cancer.

Dang CV.

Cancer Cell. 2009 Nov 6;16(5):361-2. doi: 10.1016/j.ccr.2009.10.001.

3.

Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase.

Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty AA, Moslehi JJ, Smalley DM, Wei X, Chen X, Chen Z, Beres JM, Zhang J, Tsao JL, Brenner MC, Zhang Y, Fan C, DePinho RA, Paik J, Gygi SP, Kaelin WG Jr, Zhang Q.

Genes Dev. 2014 Jul 1;28(13):1429-44. doi: 10.1101/gad.242131.114.

4.

EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.

Takada M, Zhuang M, Inuzuka H, Zhang J, Zurlo G, Zhang J, Zhang Q.

Oncotarget. 2017 Jan 24;8(4):6787-6795. doi: 10.18632/oncotarget.14290.

5.

Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response.

Koeman JM, Russell RC, Tan MH, Petillo D, Westphal M, Koelzer K, Metcalf JL, Zhang Z, Matsuda D, Dykema KJ, Houseman HL, Kort EJ, Furge LL, Kahnoski RJ, Richard S, Vieillefond A, Swiatek PJ, Teh BT, Ohh M, Furge KA.

PLoS Genet. 2008 Sep 5;4(9):e1000176. doi: 10.1371/journal.pgen.1000176. Erratum in: PLoS Genet. 2008 Jul;4(7). doi: 10.1371/annotation/7f57058f-cc02-45a6-bfab-a835619e3916.

6.

Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis.

Bordoli MR, Stiehl DP, Borsig L, Kristiansen G, Hausladen S, Schraml P, Wenger RH, Camenisch G.

Oncogene. 2011 Feb 3;30(5):548-60. doi: 10.1038/onc.2010.433. Epub 2010 Sep 20.

PMID:
20856199
7.

Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients.

Peurala E, Koivunen P, Bloigu R, Haapasaari KM, Jukkola-Vuorinen A.

Breast Cancer Res Treat. 2012 May;133(1):179-88. doi: 10.1007/s10549-011-1750-5. Epub 2011 Aug 30.

PMID:
21877141
8.
9.

Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.

Cohen B, Shimizu M, Izrailit J, Ng NF, Buchman Y, Pan JG, Dering J, Reedijk M.

Breast Cancer Res Treat. 2010 Aug;123(1):113-24. doi: 10.1007/s10549-009-0621-9. Epub 2009 Nov 14.

PMID:
19915977
10.
11.

Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.

Xiong G, Deng L, Zhu J, Rychahou PG, Xu R.

BMC Cancer. 2014 Jan 2;14:1. doi: 10.1186/1471-2407-14-1.

12.

L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells.

Chung LC, Tsui KH, Feng TH, Lee SL, Chang PL, Juang HH.

Am J Physiol Cell Physiol. 2012 Feb 15;302(4):C676-85. doi: 10.1152/ajpcell.00180.2011. Epub 2011 Nov 23.

13.
14.

Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers.

Dong Y, Asch HL, Medina D, Ip C, Ip M, Guzman R, Asch BB.

Int J Cancer. 1999 Jun 11;81(6):930-8.

15.

Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.

Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ.

Breast Cancer Res. 2010;12(3):R32. doi: 10.1186/bcr2586. Epub 2010 Jun 4.

16.

Examining the role of cyclin D1 in breast cancer.

Velasco-Velázquez MA, Li Z, Casimiro M, Loro E, Homsi N, Pestell RG.

Future Oncol. 2011 Jun;7(6):753-65. doi: 10.2217/fon.11.56. Review.

PMID:
21675838
17.

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon KL, Verhaak RG, Yan H, Kaelin WG Jr.

Nature. 2012 Feb 15;483(7390):484-8. doi: 10.1038/nature10898.

18.

Analysis of the role of the HIF hydroxylase family members in erythropoiesis.

Fisher TS, Lira PD, Stock JL, Perregaux DG, Brissette WH, Ozolins TR, Li B.

Biochem Biophys Res Commun. 2009 Oct 30;388(4):683-8. doi: 10.1016/j.bbrc.2009.08.058. Epub 2009 Aug 14.

PMID:
19683512
19.

Homeobox gene CDX2 inhibits human pancreatic cancer cell proliferation by down-regulating cyclin D1 transcriptional activity.

Takahashi K, Hirano F, Matsumoto K, Aso K, Haneda M.

Pancreas. 2009 Jan;38(1):49-57. doi: 10.1097/MPA.0b013e31817fa2ba.

PMID:
19106744
20.

Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer.

Kronblad A, Helczynska K, Nielsen NH, Påhlman E, Emdin S, Påhlman S, Landberg G.

In Vivo. 2003 Jul-Aug;17(4):311-8.

PMID:
12929585

Supplemental Content

Support Center